Synonym
SV293; SV-293; SV 293;
IUPAC/Chemical Name
1-(5-Methoxy-1H-indol-3-ylmethyl)-4-(4-methylsulfanyl-phenyl)-piperidin-4-ol
InChi Key
LIFHVPXIKLLTMH-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H26N2O2S/c1-26-18-5-8-21-20(13-18)16(14-23-21)15-24-11-9-22(25,10-12-24)17-3-6-19(27-2)7-4-17/h3-8,13-14,23,25H,9-12,15H2,1-2H3
SMILES Code
OC1(C2=CC=C(SC)C=C2)CCN(CC3=CNC4=C3C=C(OC)C=C4)CC1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
382.52
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Rangel-Barajas C, Malik M, Vangveravong S, Mach RH, Luedtke RR. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response in male DBA/2J mice: I. Effects of D2/D3 and D2 dopamine receptor selective compounds. Neuropharmacology. 2014 Aug;83:18-27. doi: 10.1016/j.neuropharm.2014.03.003. Epub 2014 Mar 26. PubMed PMID: 24680675.
2: Huang R, Griffin SA, Taylor M, Vangveravong S, Mach RH, Dillon GH, Luedtke RR. The effect of SV 293, a D2 dopamine receptor-selective antagonist, on D2 receptor-mediated GIRK channel activation and adenylyl cyclase inhibition. Pharmacology. 2013;92(1-2):84-9. doi: 10.1159/000351971. Epub 2013 Aug 10. PubMed PMID: 23942137.
3: Luedtke RR, Mishra Y, Wang Q, Griffin SA, Bell-Horner C, Taylor M, Vangveravong S, Dillon GH, Huang RQ, Reichert DE, Mach RH. Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds. ACS Chem Neurosci. 2012 Dec 19;3(12):1050-62. doi: 10.1021/cn300142q. Epub 2012 Oct 12. PubMed PMID: 23259040; PubMed Central PMCID: PMC3526968.
4: Kumar R, Riddle LR, Griffin SA, Chu W, Vangveravong S, Neisewander J, Mach RH, Luedtke RR. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology. 2009 May-Jun;56(6-7):956-69. doi: 10.1016/j.neuropharm.2009.01.019. Epub 2009 Feb 5. PubMed PMID: 19371586; PubMed Central PMCID: PMC4106465.
